特别提示： 1、截至 2023 年 11 月 6 日，广州万孚生物技术股份有限公司（以下简称 "公司"）股票已触发"万孚转债"转股价格向下修正条款。 2、公司于 2023 年 11 月 6 日召开第四届董事会第二十五次会议，审议通 过了《关于不向下修正"万孚转债"转股价格的议案》，公司董事会决定本次 不向下修正"万孚转债"转股价格，且自董事会审议通过次日起未来六个月内 （即 2023 年 11 月 7 日至 2024 年 5 月 6 日），如再次触发"万孚转债"转股价 格向下修正条款，亦不提出向下修正方案。自 2024 年 5 月 7 日起算，若再次 触发"万孚转债"转股价格的向下修正条款，届时公司董事会将再次召开会议 决定是否行使"万孚转债"转股价格的向下修正权利。 公司于 2023 年 11 月 6 日召开了第四届董事会第二十五次会议，审议通过 了《关于不向下修正"万孚转债"转股价格的议案》，具体情况如下： 一、可转债发行上市概况 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2023-066 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转 ...

二、问答环节 1、Q：国际业务目前增长的动力有哪些因素，是否受地缘政治影响？ 证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 广州万孚生物技术股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访□业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他：电话会议，投资者线上交流会 | | 参与单位名称及 | 中国银河证券股份有限公司、中信证券股份有限公司、信达证券股份有限公 | | 人员姓名 | 司、中泰证券股份有限公司、华创证券股份有限公司、太平洋证券股份有限 | | | 公司、海通证券股份有限公司、中信建投证券股份有限公司等 | | 时间 | 2023 年 10 月 26 日 | | 地点 | 电话会议 | | 上市公司接待人 | 董事会秘书：胡洪 | | 员姓名 | 财务总监：余芳霞 | | | 证券事务代表：华俊 | | | 一、2023 年三季度经营情况介绍： | | | 公司第三季度合并报表层面实现收入 5.16 亿，同比下降 22 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥515,782,939.70, a decrease of 22.18% compared to the same period last year[12]. - The net profit attributable to shareholders for Q3 2023 was ¥65,307,986.60, an increase of 5.38% year-on-year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥41,827,818.23, a slight decrease of 0.31% compared to the previous year[12]. - The company reported a significant decrease in total operating income for the year-to-date period, amounting to ¥2,004,422,655.85, down 57.32% year-on-year[18]. - The net profit for the third quarter of 2023 is approximately ¥397.69 million, a decrease from ¥1.23 billion in the same period last year, representing a decline of about 67.7%[21]. - The total profit for the quarter is reported at ¥459.49 million, down from ¥1.43 billion year-over-year, indicating a decrease of approximately 67.8%[21]. - The company's operating profit stands at ¥462.77 million, significantly lower than ¥1.44 billion in the previous year, reflecting a decline of around 67.8%[21]. - The other comprehensive income attributable to the parent company is ¥2.22 million, down from ¥10.89 million in the previous year, reflecting a decline of about 79.6%[21]. - Basic and diluted earnings per share decreased from CNY 2.81 to CNY 0.91, a decline of approximately 67.7%[36]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥5,767,049,634.88, down 8.48% from the end of the previous year[12]. - Total non-current assets decreased from CNY 2,950,749,799.06 to CNY 2,611,242,678.16, a reduction of approximately 11.5%[32]. - Total assets decreased from CNY 6,301,138,498.06 to CNY 5,767,049,634.88, reflecting a decline of about 8.5%[33]. - The total liabilities decreased from CNY 1,763,580,723.22 to CNY 1,022,610,803.14, a reduction of approximately 42.0%[33]. - Current liabilities decreased significantly from CNY 1,141,054,967.76 to CNY 347,878,783.27, a decrease of approximately 69.5%[32]. Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥36,263,870.38, a decline of 103.37% year-on-year[12]. - Net cash flow from operating activities turned negative at CNY -36,263,870.38 compared to a positive CNY 1,076,944,403.73 in the previous period[37]. - Cash inflow from financing activities totals $51,683,680.83, a decrease from $279,485,215.78 in the previous period, reflecting a decline of about 81.5%[40]. - Cash outflow from financing activities is $470,649,566.21, up from $214,120,237.95 in the previous period, indicating an increase of approximately 120.4%[40]. - The company reported a net cash decrease of $428,112,939.92 for the current period, compared to a decrease of $771,536,348.19 in the previous period[40]. Investments and Expenses - The company experienced a 36.96% decrease in cash and cash equivalents, totaling ¥732,820,331.18, primarily due to investments in financial products[18]. - The company’s development expenses increased by 34.75% to ¥69,750,299.34, attributed to increased product registration and development costs[18]. - The company reported a 60.48% increase in financial income, amounting to ¥15,191,469.21, due to higher interest income from bank deposits[18]. - Research and development expenses for the current period are $259,473,251.75, down from $309,398,871.02 in the previous period, representing a decrease of about 16.1%[43]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 55,265, with the top ten shareholders holding a significant portion of the shares[25]. - The company has a significant shareholder relationship, with the controlling shareholders holding a combined 33.17% of the total shares[28].

关于 2023 年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300482 | 证券简称：万孚生物 公告编号：2023-064 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 特别提示： | 证券代码：300482 | | 证券简称：万孚生物 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：123064 | | 债券简称：万孚转债 | | | | | | | 转股价格：人民币 | 元/股 51.23 | | | | | | | | 转股时间：2021 年 | 3 月 8 日至 | 2026 | 年 | 8 | 月 | 31 | 日 | 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所可转换公司 债券业务实施细则》的有关规定，广州万孚生物技术股份有限公司（以下简称"公 司"）现将 2023 年第三季度可转换公司债券（以下简称"可转债"）转股 ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2023-062 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于万孚转债2023年付息的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、"万孚转债"（债券代码：123064）将于 2023 年 9 月 1 日支付第三年利息， 每 10 张"万孚转债"（面值 1,000 元）利息为 10.00 元（含税）。 2、债权登记日：2023 年 8 月 31 日； 3、除息日：2023 年 9 月 1 日； 4、付息日：2023 年 9 月 1 日； 5、本次付息期间及票面利率：计息期间为 2022 年 9 月 1 日至 2023 年 8 月 31 日，票面利率为 1.00%； 6、"万孚转债"本次付息的债权登记日为 2023 年 8 月 31 日，截至 2023 年 8 月 31 日下午深圳证券交易所收市后，在中国证券登记结算有限责任公司深圳分 公司（以下简称"中国结算深圳分公司"）登记在册的"万孚转债"持有人 ...

证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 广州万孚生物技术股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访□业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他：电话会议，投资者线上交流会 | | 参与单位名称及 | 中国银河证券股份有限公司、中信证券股份有限公司、信达证券股份有限公 | | 人员姓名 | 司、中信建投证券股份有限公司、华创证券股份有限公司、国金证券股份有 | | | 限公司等 | | 时间 | 2023 年 8 月 16 日 | | 地点 | 电话会议 | | 上市公司接待人 | 董事长：王继华 | | 员姓名 | 董事会秘书：胡洪 | | | 财务总监：余芳霞 | | | 证券事务代表：华俊 一、2023 年上半年经营情况介绍： | | | 今年以来，公司将"质量和成本"作为公司战略底座，将"国际化融合" 上升为公司级业务战略，从"有规模的增长"转向"有质量的增长"。在报告 | | | 期内公司实现收入 14. ...

Technology and Innovation - The company has established a dual control system for biological raw material technology and production technology platforms, ensuring stable supply and long-term development[8]. - The company completed the acquisition of Shenzhen Tianshen Medical, enhancing its product offerings in the chemiluminescence field and strengthening its competitive position[9]. - The company has formed a comprehensive solution capability for pathology departments, covering mainstream subfields of organizational pathology, cytopathology, and molecular pathology[9]. - The company is continuously optimizing its product pipeline, focusing on reliable testing products to enhance business competitiveness[18]. - The company has established a comprehensive technology platform and product line, making it a leading enterprise in the domestic POCT industry[55]. - The company has established nine major technology platforms, resulting in a rich product line for various diagnostic fields, with products sold in over 150 countries and regions[69]. - The company has implemented a quality management system compliant with international standards, including FDA and CE certifications, enhancing its manufacturing capabilities since 2004[78]. - The company has established a strong R&D team of 750 professionals across multiple locations, ensuring industry-leading research and development capabilities[160]. - The company has obtained 22 authorized patents/software copyrights during the reporting period, with a total of 424 valid patents as of June 30, 2023[120]. Market Position and Strategy - The company focuses on six key disease categories: cardiovascular and metabolic diseases, tumors, respiratory diseases, infectious diseases, maternal and child health, and drug abuse, aiming to strengthen its market position as an IVD industry leader[12]. - The company is committed to a strategy of "immunodiagnosis as the main focus" in the domestic market and "both immunology and molecular diagnostics" in the overseas market[18]. - The company is actively participating in the national "Comprehensive Quality Improvement Action Plan" to enhance POCT quality management and major disease diagnosis[11]. - The company continues to promote and incentivize critical care medical centers in the domestic market, optimizing pricing strategies and focusing on key markets to accelerate the replacement of imported competitors[19]. - The company's products are sold in over 150 countries and regions, with a focus on deepening market penetration in key countries and enhancing channel construction[22]. - The company has established a global marketing structure with dedicated teams for domestic, international, and U.S. markets, enhancing its marketing effectiveness[74]. - The company has a dual business model of "2B+2C," which expands marketing channels and enriches application scenarios, contributing to new growth points in performance[148]. Financial Performance - The company's operating revenue for the reporting period was ¥1,488,639,716.15, a decrease of 63.09% compared to the same period last year[44]. - Net profit attributable to shareholders was ¥334,503,325.44, down 71.60% year-over-year[44]. - The net profit after deducting non-recurring gains and losses was ¥295,482,365.98, reflecting a decline of 74.01% compared to the previous year[44]. - The net cash flow from operating activities was -¥94,946,066.41, a decrease of 108.42% from the same period last year[44]. - Basic and diluted earnings per share were both ¥0.76, down 71.54% year-over-year[44]. - Total assets at the end of the reporting period were ¥5,845,023,109.31, a decrease of 7.24% from the end of the previous year[44]. - The net assets attributable to shareholders increased by 3.55% to ¥4,498,116,102.92 compared to the end of the previous year[44]. - The company achieved revenue of 427.61 million yuan from infectious disease business, a decrease of 86.67% compared to the same period last year[103]. - Revenue from chronic disease management testing reached 717.82 million yuan, an increase of 40.30% year-on-year[108]. - The company’s gross profit margin has improved due to the implementation of new technologies and processes in production and operations[105]. Investment and Expansion - In the first half of 2023, the company invested in Beijing Puyi Biotechnology to advance tumor companion diagnosis and early screening, as well as genetic and rare disease diagnostic technology[9]. - The company is in a rapid growth phase, requiring significant funding for capacity expansion, product development, and channel optimization, leading to a refinancing initiative in the second half of 2022[84]. - The company has committed to invest ¥29,161.86 million in the chemical luminescence technology platform project, with an investment progress of 104.46% as of June 30, 2023[175]. - The molecular diagnostic platform R&D project has an investment progress of 104.78%, with a total investment of ¥12,318.68 million as of September 30, 2023[175]. - The total amount of raised funds is CNY 589.19 million, with CNY 51.59 million invested during the reporting period[188]. - Cumulative investment of raised funds reached CNY 609.75 million, with no changes in the purpose of the raised funds[188]. - The company has invested CNY 560 million in Guangzhou Wanxin Industrial Development Co., holding a 100% stake, and CNY 300 million in Beijing Puyi Biotechnology Co., holding a 6.25% stake[185]. Challenges and Risks - The company faces risks related to distributor management, new product development, quality control, and policy changes[192]. - The National Medical Insurance Bureau is implementing a standardized management system for medical consumables, which will impact the company's operations and market strategies[42]. - The company has not reported any ongoing litigation related to its investments[185].

广州万孚生物技术股份有限公司 2023年上半年度募集资金存放与使用情况专项报告 广州万孚生物技术股份有限公司 2023年上半年度募集资金存放与使用情况专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 以及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式（2023 年修订）》的相关规定，本公司将截至 2023 年 6 月 30 日止募集资金存放与使用 情况作如下专项报告： 1、募集资金使用计划 本公司《向不特定对象发行可转换公司债券募集说明书》载明的募投项目及 募集资金使用计划为： 单位：万元 专项报告第 1 页 广州万孚生物技术股份有限公司 2023年上半年度募集资金存放与使用情况专项报告 | 序号 | 项目名称 | 总投资额 | 拟投入募集资金 | 建设期（月） | | --- | --- | --- | --- | --- | | 1 | 化学发光技术平台 产业化建设项目 | 34,295.79 | ...

广州万孚生物技术股份有限公司 独立董事关于第四届董事会第二十三次会议 相关事项的事前认可意见 广州万孚生物技术股份有限公司（以下简称"公司"）于第四届董事会第二 十三次会议召开前向独立董事提交了本次董事会的相关材料，我们作为公司的独 立董事，根据《公司章程》、《董事会议事规则》、《独立董事工作细则》等相关规 章制度的有关规定，本着审慎的原则，基于独立判断的立场，对公司相关材料进 行了认真的事前审查，并发表如下意见： 一、关于公司及控股子公司增加 2023 年度日常关联交易预计的事前认可意 见 我们对公司及控股子公司增加 2023 年度日常关联交易的预计情况进行了事 前审核，我们认为：公司已将上述关联交易事项事先与我们进行了沟通，我们审 阅了相关材料，我们一致同意该议案提交公司董事会审议，董事会在审议本次关 联交易事项时，关联董事均回避表决。 （以下无正文） （本页无正文，为《广州万孚生物技术股份有限公司独立董事关于第四届董事会 第二十三次会议相关事项的事前认可意见》之签字页） 独立董事： 陈锦棋 李从东 段朝晖 广州万孚生物技术股份有限公司 2023 年 8 月 15 日 ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2023-060 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于延长公司 2022 年度创业板向特定对象发行股票股东大会决议有 效期及股东大会对董事会授权有效期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于）于 2023 年 8 月 15 日召开了第四届董事会第二十三次会议，审议通过了《关于延长公司 2022 年度 创业板向特定对象发行股票股东大会决议有效期的议案》及《关于提请股东大会 延长授权董事会全权办理公司 2022 年度创业板向特定对象发行股票相关事宜的 议案》，同日公司召开了第四届监事会第十七次会议，审议通过了《延长公司 2022 年度创业板向特定对象发行股票股东大会决议有效期的议案》。公司独立董事对 上述事项发表了同意的独立意见。现将有关事项说明如下： 一、关于延长公司 2022 年度创业板向特定对象发行股票股东大会决议有效 期及股东大会对董事会授权有效 ...